Clinical Trial

Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma

Name: Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma — clinical trial record (NCT06956716)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The main purpose of this study is to evaluate the feasibility and safety of personalized tumor neoantigen mRNA therapy iNeo-Vac-R01 combined with PD-1 monoclonal antibody and standard chemotherapy regimen for the treatment of patients with advanced intrahepatic cholangiocarcinoma.

Trial Details

NCT Number	NCT06956716
Lead Sponsor	Zhejiang University Collaborators: Hangzhou Neoantigen Therapeutics Co., Ltd.
Conditions	Advanced Intrahepatic Cholangiocarcinoma
Enrollment	30 participants
Start Date	2025-04-09
Primary Completion	2027-04-01 (estimated)
Study Completion	2028-04-01 (estimated)
Updated on ClinicalTrials.gov	2025-05-04